Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    60.0%

    Based on 3 completed trials

    Completion Rate
    60%(3/5)
    Active Trials
    0(0%)
    Results Posted
    0%(0 trials)
    Terminated
    2(40%)

    Phase Distribution

    Phase 3
    1
    20%
    Not Applicable
    2
    40%
    Phase 4
    1
    20%

    Phase Distribution

    0

    Early Stage

    0

    Mid Stage

    2

    Late Stage

    Phase Distribution4 total trials
    Phase 3Large-scale testing
    1(25.0%)
    Phase 4Post-market surveillance
    1(25.0%)
    N/ANon-phased studies
    2(50.0%)

    Highest Phase Reached

    Phase 4

    Trial Status & Enrollment

    Completion Rate

    60.0%

    3 of 5 finished

    Non-Completion Rate

    40.0%

    2 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    5

    all time

    Status Distribution
    Completed(3)
    Terminated(2)

    Detailed Status

    Completed3
    Terminated2

    Development Timeline

    Analytics

    Development Status

    Total Trials
    5
    Active
    0
    Success Rate
    60.0%
    Most Advanced
    Phase 4

    Trials by Phase

    Phase 31 (25.0%)
    Phase 41 (25.0%)
    N/A2 (50.0%)

    Trials by Status

    completed360%
    terminated240%

    Recent Activity

    0 active trials
    Showing 5 of 5
    terminated

    Effectiveness and Safety of Combination Mifepristone/Misoprostol for Medical Abortion

    NCT04905251
    completedphase_4

    Mifepristone and Misoprostol for Fetal Demise

    NCT00177372
    completednot_applicable

    Mifepristone and Misoprostol Versus Misoprostol Alone for Mid-trimester Termination of Pregnancy (14 - 21 Weeks LMP): A Randomized-controlled Double-blinded Trial

    NCT00784186
    completednot_applicable

    Mifepristone Plus Misoprostol Versus Misoprostol Alone for 2nd Trimester Abortion (14 - 21 Weeks Last Menstrual Period (LMP))

    NCT00969982
    terminatedphase_3

    Mifepristone and Misoprostol Versus Misoprostol Alone for Mid-trimester Termination of Pregnancy (14-21 Weeks LMP)

    NCT00957346

    Clinical Trials (5)

    Showing 5 of 5 trials
    NCT04905251

    Effectiveness and Safety of Combination Mifepristone/Misoprostol for Medical Abortion

    Terminated
    NCT00177372Phase 4

    Mifepristone and Misoprostol for Fetal Demise

    Completed
    NCT00784186Not Applicable

    Mifepristone and Misoprostol Versus Misoprostol Alone for Mid-trimester Termination of Pregnancy (14 - 21 Weeks LMP): A Randomized-controlled Double-blinded Trial

    Completed
    NCT00969982Not Applicable

    Mifepristone Plus Misoprostol Versus Misoprostol Alone for 2nd Trimester Abortion (14 - 21 Weeks Last Menstrual Period (LMP))

    Completed
    NCT00957346Phase 3

    Mifepristone and Misoprostol Versus Misoprostol Alone for Mid-trimester Termination of Pregnancy (14-21 Weeks LMP)

    Terminated

    All 5 trials loaded

    Drug Details

    Intervention Type
    Drug
    Total Trials
    5